Form 4: Recursion Pharmaceuticals COO Tina Marriott Executes Stock Option and Sells Shares Under 10b5-1 Plan

Tina Marriott, President and COO of Recursion Pharmaceuticals, exercised stock options and sold 6,000 shares of Class A Common Stock at an average price of $8.1349, according to a recent SEC Form 4 filing.

Summary

• On July 25, 2024, Tina Marriott, the President and COO of Recursion Pharmaceuticals, executed a transaction involving the company's Class A Common Stock.
• Marriott exercised stock options to acquire 6,000 shares at a price of $1.06 per share.
• Simultaneously, Marriott sold 6,000 shares at a weighted average price of $8.1349, with individual sales prices ranging from $7.73 to $8.5.
• These transactions were executed under a pre-arranged 10b5-1 trading plan established on March 1, 2024.
• Following these transactions, Marriott directly owns 535,457 shares of Class A Common Stock.
• Marriott also holds options to purchase a total of 1,239,049 additional shares at various exercise prices and expiration dates.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports transactions by an officer. There is no indication of positive or negative sentiment towards the company.

Industry Context

This filing is a routine disclosure of insider transactions. It is common for executives to utilize 10b5-1 trading plans to manage their stock holdings and avoid accusations of insider trading. The filing provides transparency into the trading activities of a key executive at Recursion Pharmaceuticals.

Comparison to Industry Standards

• Insider transactions are a common occurrence in publicly traded companies.
• Executives often use 10b5-1 plans to automate stock sales and exercises.
• The details provided in the Form 4 filing are standard for this type of disclosure.
• Comparable companies such as Exscientia, Schrodinger, and Relay Therapeutics also have executives who regularly file Form 4s related to stock transactions.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by a key executive.
• The 10b5-1 plan ensures that the transactions are pre-planned and not based on inside information.

Key Dates